Impressive anti-tumor activity of combined erbB1 and erbB2 blockade with OSI-774 (eriotinib; E) and trastuzumab (T) in combination with weekly paclitaxel (P) in patients (pts) with trastuzumab refractory breast cancer in a phase I pharmacokinetics (PK) study.

被引：0
|
作者：
Rodon, J. [1 ]
Beeram, M. [1 ]
de Bono, J. S. [1 ]
Patnaik, A. [1 ]
Mita, A. [1 ]
O'Rourke, P. [1 ]
Bruno, S. [1 ]
Papadapoulos, K. [1 ]
Takimoto, C. [1 ]
Tolcher, A. [1 ]
机构：
[1] Canc Therapy & Res Ctr S Texas, San Antonio, TX 78229 USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2006年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S68 / S69
页数：2
相关论文
共 5 条
  • [1] Impressive anti-tumor activity of combined erbB1 and erbB2 blockade: a phase I and pharmacokinetics (PK) study of OSI-774 (Erlotinib; E) and Trastuzumab (T) in combination with weekly Paclitaxel (P) in patients (pts) with advanced solid tumors
    Beeram, M.
    De Bono, J. S.
    Rowinsky, E. K.
    O'Rourke, P.
    Ricart, A.
    Hammond, L. A.
    Patnaik, A.
    Mita, M.
    Mita, A.
    Tolcher, A. W.
    EJC SUPPLEMENTS, 2006, 4 (12): : 183 - 183
  • [2] Phase I and pharmacokinetics (PK) of combined erbB1 and erbB2 blockade with OSI-774 (Erlotinib; E) and trastuzumab (T) in combination with weekly paclitaxel (P) in patients (pts) with advanced solid tumors
    Beeram, M
    De Bono, JS
    Patnaik, A
    Mita, A
    Chu, SC
    Mita, MM
    O'Rourke, P
    Takimoto, CH
    Tolcher, AW
    Rowinsky, EK
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S95 - S95
  • [3] Phase I and pharmacokinetics (PK) of combined erbB1 and erbB2 blockade with OSI-774 (erlotinib; E) and trastuzumab (T) in combination with weekly paclitaxel (P) in patients (pts) with advanced solid tumors.
    Patnaik, A
    Beeram, M
    de Bono, JS
    Mita, A
    Chu, SC
    Rowinsky, EK
    Schwartz, G
    O'Rourke, P
    Takimoto, CH
    Tolcher, AW
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 135S - 135S
  • [4] A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer
    Arteaga, Carlos L.
    O'Neill, Anne
    Moulder, Stacy L.
    Pins, Michael
    Sparano, Joseph A.
    Sledge, George W.
    Davidson, Nancy E.
    CLINICAL CANCER RESEARCH, 2008, 14 (19) : 6277 - 6283
  • [5] A Phase lb Study Evaluating Safety, Tolerability, Pharmacokinetics (PK), and Activity of the Phosphoinositide-3 Kinase (PI3K) Inhibitor GDC-0941 in Combination with Trastuzumab-MCC-DM1 (T-DM1) in Patients with Advanced HER2-Positive Breast Cancer
    Krop, I. E.
    Wolff, A. C.
    Winer, E. P.
    Miller, K. D.
    Park, B. H.
    Ware, J.
    Holden, S.
    Levy, G. G.
    Derynck, M.
    Storniolo, A. M.
    CANCER RESEARCH, 2010, 70
1